Akura Medical has secured a $53 million first close for its Series C financing round, marking a significant step toward expanding its venous thromboembolism technology portfolio and accelerating commercial readiness. The round was led by Qatar Investment Authority, with participation from existing investors, and will also support the establishment of a new joint venture in Qatar.
According to the announcement, the funding will enhance the development of both the Katana Thrombectomy System and the NavIQ quantification software. The capital is also expected to finalize enrollment in the QUADRA PE clinical trial and support regulatory submissions as the company pushes toward future market introduction. The Katana System is designed to remove various clot types using high-velocity saline jets, reduce catheter clogging, and provide real-time pulmonary artery pressure data. NavIQ is intended to convert CT angiograms into three-dimensional pulmonary models to support procedural planning and clot characterization.
Founded under the Shifamed medical innovation platform, Akura Medical focuses on technologies that aim to improve the standard of care for venous thromboembolism, which remains a significant cause of cardiovascular-related deaths in the United States. The company describes its flagship Katana System as a next-generation solution that could meaningfully reshape the treatment of pulmonary embolism.
The new Series C financing follows an extended period of product development as Akura Medical continues building toward commercial scale. Part of the proceeds will also fund international expansion through the new Qatar-based venture. The company stated that VTE impacts hundreds of thousands of patients in the United States each year, creating a substantial unmet need for more advanced treatment tools. Shifamed, the parent innovation hub founded by Amr Salahieh, emphasized its mission to accelerate medical technology innovation that improves patient outcomes and long-term health.
KEY QUOTES:
“Akura Medical is advancing a differentiated portfolio of venous thrombectomy technologies aimed at improving procedural precision and patient outcomes. The recent introduction of our NavIQ quantification software represents the next step toward intelligent, data driven thrombectomy. This new capital enables us to accelerate product development and continue building the foundation for long term growth. We appreciate QIA’s confidence and partnership as we deliver on our vision.”
Amr Salahieh, Chair and Acting Chief Executive Officer, Akura Medical
